Literature DB >> 20802087

Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction.

Navneet K Dhillon1, Fang Li, Bing Xue, Ossama Tawfik, Susan Morgello, Shilpa Buch, Amy O'Brien Ladner.   

Abstract

Human immunodeficiency virus (HIV)-associated pulmonary arterial hypertension (PAH) is a devastating, noninfectious complication of acquired immune deficiency syndrome, and the majority of HIV-PAH cases occur in individuals with a history of intravenous drug use (IVDU). However, although HIV-1 and IVDU have been associated with PAH independently or in combination, the pathogenesis of the disproportionate presence of HIV-PAH in association with IVDU has yet to be characterized. The objective of this study was to obtain a better understanding of the interactions between HIV-1 and cocaine to help uncover the mechanism(s) of the development of HIV-PAH. We observed that exposure of HIV-infected macrophages or HIV-Trans-Activator of Transcription (Tat)-treated pulmonary endothelial cells to cocaine enhanced the expression of platelet-derived growth factor (PDGF)-BB. Simultaneous treatment with Tat and cocaine, on the other hand, exacerbated both the disruption of tight junction proteins (TJPs), with enhanced permeability in pulmonary endothelial cells, and the proliferation of pulmonary smooth muscle cells (pSMCs) compared with either treatment alone. Histological examination of HIV plus IVDU human lung sections showed signs of early pulmonary arteriopathy, severe down-modulation of TJPs, and increased expression of PDGF-BB compared with the lung sections from individuals who are infected with HIV and without history of IVDU. Interestingly, blocking of PDGF receptor signaling with the receptor antagonist or small interfering RNA has been shown to inhibit the increase in proliferation of pSMCs on Tat and cocaine exposure. Our results, therefore, support an additive effect of cocaine to HIV infection in the development of pulmonary arteriopathy through enhancement of endothelial dysfunction and proliferation of pSMCs, while also suggesting PDGF-PDGF receptor axis as a potential target for use in clinical intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802087      PMCID: PMC3145070          DOI: 10.1165/rcmb.2010-0097OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  71 in total

1.  Upregulation of expression of platelet-derived growth factor and its receptor in pneumonia associated with SHIV-infected macaques.

Authors:  Navneet K Dhillon; Yongjun Sui; David Pinson; Shanping Li; Sukhbir Dhillon; Ossama Tawfik; Shannon Callen; Olga Nemon; Opendra Narayan; Shilpa Buch
Journal:  AIDS       Date:  2007-01-30       Impact factor: 4.177

2.  PDGF synergistically enhances IFN-gamma-induced expression of CXCL10 in blood-derived macrophages: implications for HIV dementia.

Authors:  Navneet Kaur Dhillon; Fuwang Peng; Richard M Ransohoff; Shilpa Buch
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 3.  Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension.

Authors:  Marc Humbert; David Montani; Frédéric Perros; Peter Dorfmüller; Serge Adnot; Saadia Eddahibi
Journal:  Vascul Pharmacol       Date:  2008-06-20       Impact factor: 5.773

4.  Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia.

Authors:  Navneet K Dhillon; Rachel Williams; Fuwang Peng; Yi-Jou Tsai; Sukhbir Dhillon; Brandon Nicolay; Milind Gadgil; Anil Kumar; Shilpa J Buch
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

Review 5.  From viral infection to pulmonary arterial hypertension: a role for viral proteins?

Authors:  Norbert F Voelkel; Carlyne D Cool; Sonia Flores
Journal:  AIDS       Date:  2008-09       Impact factor: 4.177

Review 6.  Stroke in HIV infection and AIDS.

Authors:  Michael R Dobbs; Joseph R Berger
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-10

7.  Cocaine-mediated alteration in tight junction protein expression and modulation of CCL2/CCR2 axis across the blood-brain barrier: implications for HIV-dementia.

Authors:  Navneet K Dhillon; Fuwang Peng; Sirosh Bokhari; Shannon Callen; Sun-Hye Shin; Xuhui Zhu; Kee-Jun Kim; Shilpa J Buch
Journal:  J Neuroimmune Pharmacol       Date:  2007-11-29       Impact factor: 4.147

8.  Cerebral vascular dysfunction during hypercholesterolemia.

Authors:  Jiro Kitayama; Frank M Faraci; Steven R Lentz; Donald D Heistad
Journal:  Stroke       Date:  2007-05-24       Impact factor: 7.914

9.  Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.

Authors:  Olivier Sitbon; Caroline Lascoux-Combe; Jean-François Delfraissy; Patrick G Yeni; François Raffi; Dominique De Zuttere; Virginie Gressin; Pierre Clerson; Daniel Sereni; Gérald Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2007-10-11       Impact factor: 21.405

10.  Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.

Authors:  Kirsi Vuorinen; Fei Gao; Tim D Oury; Vuokko L Kinnula; Marjukka Myllärniemi
Journal:  Exp Lung Res       Date:  2007-09       Impact factor: 2.459

View more
  33 in total

1.  Injection drug use as a "second hit" in the pathogenesis of HIV-associated pulmonary hypertension.

Authors:  M Patricia George; Hunter C Champion; Mark T Gladwin; Karen A Norris; Alison Morris
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

2.  Reactive Oxygen Species/Hypoxia-Inducible Factor-1α/Platelet-Derived Growth Factor-BB Autocrine Loop Contributes to Cocaine-Mediated Alveolar Epithelial Barrier Damage.

Authors:  Lu Yang; Xufeng Chen; Samantha M Simet; Guoku Hu; Yu Cai; Fang Niu; Yeonhee Kook; Shilpa J Buch
Journal:  Am J Respir Cell Mol Biol       Date:  2016-11       Impact factor: 6.914

3.  Pulmonary Function in HIV-Infected Recreational Drug Users in the Era of Anti-Retroviral Therapy.

Authors:  Joseph A Simonetti; Matthew R Gingo; Lawrence Kingsley; Cathy Kessinger; Lorrie Lucht; Gk Balasubramani; Joseph K Leader; Laurence Huang; Ruth M Greenblatt; John Dermand; Eric C Kleerup; Alison Morris
Journal:  J AIDS Clin Res       Date:  2014-11

Review 4.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

5.  Ligand-Independent Activation of Platelet-Derived Growth Factor Receptor β during Human Immunodeficiency Virus-Transactivator of Transcription and Cocaine-Mediated Smooth Muscle Hyperplasia.

Authors:  Pranjali N Dalvi; Vijayalaxmi G Gupta; Brooke R Griffin; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

Review 6.  Mechanisms Underlying HIV-Associated Noninfectious Lung Disease.

Authors:  Rachel M Presti; Sonia C Flores; Brent E Palmer; Jeffrey J Atkinson; Catherine R Lesko; Bryan Lau; Andrew P Fontenot; Jesse Roman; John F McDyer; Homer L Twigg
Journal:  Chest       Date:  2017-04-17       Impact factor: 9.410

7.  Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine.

Authors:  Leslie Spikes; Pranjali Dalvi; Ossama Tawfik; Haihua Gu; Norbert F Voelkel; Paul Cheney; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

Review 8.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

Review 9.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

Review 10.  Pathogenesis of HIV and the lung.

Authors:  Matthew R Gingo; Alison Morris
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.